Showing results (41-50 of 70) with videos related to
Sort By:
Pageof 7
Cancer Research|May 4, 2005
Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancerSun-Jin Kim, Hisanori Uehara, Sertac Yazici, et al.Molecular Cancer Research : MCR|June 23, 2025
A novel bispecific integrin α5β1/αv antibody reprograms the Myc-regulated basal phenotype of prostate cancer with natural killer cell-mediated tumor eliminationRaghav Joshi, Ming Zhou, Jeffrey H Lin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancerPaul Mathew, Peter F Thall, Donnah Jones, et al.Clinical Genitourinary Cancer|October 10, 2006
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancerPaul Mathew, Christopher J Logothetis, Pauline Y Dieringer, et al.The Journal of Urology|July 19, 2008
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agentsNizar M Tannir, Peter F Thall, Chaan S Ng, et al.Evidence Report/Technology Assessment|November 7, 2012
An evidence review of active surveillance in men with localized prostate cancerStanley Ip, Issa J Dahabreh, Mei Chung, et al.Journal of the National Cancer Institute|March 20, 2003
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastasesHisanori Uehara, Sun Jin Kim, Takashi Karashima, et al.Medrxiv : the Preprint Server for Health Sciences|June 8, 2021
Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-α antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failureHilal Hachem, Amandeep Godara, Courtney Schroeder, et al.Journal of Clinical and Translational Science|August 30, 2021
Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failureHilal Hachem, Amandeep Godara, Courtney Schroeder, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 12, 2025
Cost-Effectiveness of Enfortumab Vedotin and Pembrolizumab for First-Line Metastatic Urothelial Cancer in the United StatesTanvi V Chiddarwar, Hawre Jalal, Fernando Alarid-Escudero, et al.Pageof 7